Cosmo Technologies Ltd Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Dublin Ireland (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2008
NCT03447821
First Marketed Drug
2018
rifamycin (aemcolo)
First NDA Approval
2018
rifamycin (aemcolo)
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

COSMO TECHNOLOGIES | Cosmo Technologies Ltd